ALK-Abelló A/S (ALK-B.CO)

DKK 145.5

(0.97%)

Total Debt Summary of ALK-Abelló A/S

  • ALK-Abelló A/S's latest annual total debt in 2023 was 765 Million DKK , up 9.91% from previous year.
  • ALK-Abelló A/S's latest quarterly total debt in 2024 Q2 was 507 Million DKK , down -2.12% from previous quarter.
  • ALK-Abelló A/S reported annual total debt of 696 Million DKK in 2022, down -1.97% from previous year.
  • ALK-Abelló A/S reported annual total debt of 710 Million DKK in 2021, down -24.71% from previous year.
  • ALK-Abelló A/S reported quarterly total debt of 518 Million DKK for 2024 Q1, down -32.29% from previous quarter.
  • ALK-Abelló A/S reported quarterly total debt of 730 Million DKK for 2023 Q2, up 14.24% from previous quarter.

Annual Total Debt Chart of ALK-Abelló A/S (2023 - 2005)

Historical Annual Total Debt of ALK-Abelló A/S (2023 - 2005)

Year Total Debt Total Debt Growth
2023 765 Million DKK 9.91%
2022 696 Million DKK -1.97%
2021 710 Million DKK -24.71%
2020 943 Million DKK -4.75%
2019 990 Million DKK 33.42%
2018 742 Million DKK -2.11%
2017 758 Million DKK -2.19%
2016 775 Million DKK 20.16%
2015 645 Million DKK 99.07%
2014 324 Million DKK -0.92%
2013 327 Million DKK -1.51%
2012 332 Million DKK -0.6%
2011 334 Million DKK 595.83%
2010 48 Million DKK 860.0%
2009 5 Million DKK -75.0%
2008 20 Million DKK -71.01%
2007 69 Million DKK -17.86%
2006 84 Million DKK -1.18%
2005 85 Million DKK 0.0%

Peer Total Debt Comparison of ALK-Abelló A/S

Name Total Debt Total Debt Difference
Bavarian Nordic A/S 145.3 Million DKK -426.49%
Genmab A/S 770 Million DKK 0.649%
Gubra A/S 71.43 Million DKK -970.904%
Novo Nordisk A/S 27 Billion DKK 97.167%
Orphazyme A/S - DKK -Infinity%
Pharma Equity Group A/S 30.22 Million DKK -2431.352%
Zealand Pharma A/S 200.27 Million DKK -281.975%